Efficacy of carboxytherapy in treatment vitiligo

Efficacy of carboxytherapy versus topical 0.1% tacrolimus ointment in treatment of localized non-segmental vitiligo

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250122064474N1

Enrollment

Registered

2025-04-03

Start date

2025-04-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Control group: On the control side, 0.1% tacrolimus ointment manufactured by the Iranian company Abu Raihan under the trade name Moduproc is prescribed. The patient is instructed to ap

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Informed consent to participate in the study Any skin phototype Localized non-segmental vitiligo involving <10% of body surface area No new lesions have appeared in the past 6 months Relatively symmetrical distribution of lesions on both the right and left sides

Exclusion criteria

Exclusion criteria: Conflict of ends White hair in target lesions Pregnancy and breastfeeding Smoking, alcohol, and drug abuse Having systemic diseases, including diabetes, kidney disease, heart disease, respiratory disease, liver disease, anemia, etc. Having connective tissue diseases or genodermatoses Receiving medication to treat vitiligo 6 weeks ago Taking any medications or supplements

Design outcomes

Primary

Measure	Time frame
The variable under study is actually the response to clinical treatment of vitiligo and is evaluated based on clinical criteria such as size, repigmentation pattern, side effects, pain, and patient satisfaction. Timepoint: Clinical examination and high-resolution digital radiography will be used to assess outcomes at time zero, before each carboxytherapy session, and two weeks after the last session. Patients will be followed for 14 weeks from study enrollment. Method of measurement: Various tools will used for clinical studies, including: the investigator's overall assessment criteria, which indicate the outcome of the response to treatment from the perspective of the study's researcher, the symptom sum scoring criteria, which are determined by symptoms such as the size and pattern of repigmentation and erythema, the pain measurement scale, the assessment of patient satisfaction based on a ten-point scale, and the assessment of skin phototype based on the tables mentioned.	—

Measure

Time frame

The variable under study is actually the response to clinical treatment of vitiligo and is evaluated based on clinical criteria such as size, repigmentation pattern, side effects, pain, and patient satisfaction. Timepoint: Clinical examination and high-resolution digital radiography will be used to assess outcomes at time zero, before each carboxytherapy session, and two weeks after the last session. Patients will be followed for 14 weeks from study enrollment. Method of measurement: Various tools will used for clinical studies, including: the investigator's overall assessment criteria, which indicate the outcome of the response to treatment from the perspective of the study's researcher, the symptom sum scoring criteria, which are determined by symptoms such as the size and pattern of repigmentation and erythema, the pain measurement scale, the assessment of patient satisfaction based on a ten-point scale, and the assessment of skin phototype based on the tables mentioned.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hosein Ahmadi

Arak University of Medical Sciences

Mohammadhosein2001ahmadi@gmail.com+98 86 3497 7190

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026